Company Encyclopedia
View More
name
YESTAR HEALTH
02393.HK
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents.
78.78 B
02393.HKMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
D
Health Care SuppliesIndustry
Industry Ranking12/12
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-29.75%E
    • Profit Margin-8.35%D
    • Gross Margin16.66%D
  • Growth ScoreE
    • Revenue YoY-28.45%E
    • Net Profit YoY-115.13%E
    • Total Assets YoY-24.56%E
    • Net Assets YoY-21.59%E
  • Cash ScoreE
    • Cash Flow Margin-1197.77%E
    • OCF YoY-28.45%E
  • Operating ScoreA
    • Turnover1.21A
  • Debt ScoreD
    • Gearing Ratio61.67%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yestar Healthcare Plans Joint Venture to Expand Precision Oncology Services in Southeast Asia

    Yestar Healthcare Holdings Co Ltd plans to form a joint venture with New Genetron Holding Limited in Singapore to establish clinical molecular diagnostics laboratories in Indonesia. This initiative aims to enhance precision oncology services, including early cancer screening and genomic profiling, utilizing Genetron Health’s technology. The venture is expected to strengthen Yestar’s market presence in Southeast Asia and foster collaborations with Indonesian healthcare institutions. Yestar is involved in distributing IVD products and manufacturing medical imaging films in China, with a current market cap of HK$295.9M.

    Tip Ranks·
    HK
    02393
    -1.74%
    Tip Ranks·
    HK
    02393
    -1.74%

    YESTAR HEALTH is considering establishing a joint venture with Genetron Health in Singapore and may develop business in Indonesia, Malaysia, and Singapore

    YESTAR HEALTH is considering establishing a joint venture with Genetron Health in Singapore, planning to develop business in Indonesia, Malaysia, and Singapore. The joint venture will focus on precision oncology, setting up clinical molecular diagnostic laboratories to provide cancer screening and genetic testing, helping doctors detect diseases early and formulate personalized treatment plans. The main products include early cancer screening, comprehensive genomic analysis, and non-invasive prenatal testing

    Zhitong·
    HK
    02393
    -1.74%
    Zhitong·
    HK
    02393
    -1.74%

    Yestar Healthcare Holdings Announces Full Repayment of Loan and Release of Pledged Shares

    Yestar Healthcare Holdings Co. Ltd. announced the full repayment of a loan by non-executive director Mr. Hartono James, which was secured by pledged shares. Following this repayment, the company is initiating the release of all previously charged shares, with no remaining shares pledged. Shareholders and potential investors are advised to exercise caution when trading the company's shares.

    Reuters·
    HK
    02393
    -1.74%
    Reuters·
    HK
    02393
    -1.74%

    "Performance" YESTAR HEALTH's net profit for the half year is 5.761 million RMB, down 99.5%

    YESTAR HEALTH announced its interim results for the period ending June this year, with revenue from continuing operations of RMB 803 million, a year-on-year decrease of 37%. Net profit was RMB 5.761 million, a year-on-year decrease of 99.5%; earnings per share were 0.25 cents. No dividend was declared

    AASTOCKS·
    HK
    02393
    -1.74%
    AASTOCKS·
    HK
    02393
    -1.74%

    YESTAR HEALTH announced its interim results, with profit attributable to owners of the company amounting to HKD 5.761 million, a year-on-year decrease of 99.47%

    According to the Zhitong Finance APP, YESTAR HEALTH announced its mid-term results for 2025, with continuing operations revenue of approximately HKD 803 million, a year-on-year decrease of 36.99%; profit attributable to the company's owners was HKD 5.761 million, a year-on-year decrease of 99.47%; earnings per share were 0.25 cents. The announcement stated that both revenue and gross profit margin declined simultaneously, mainly due to the impact of China's centralized procurement policy on the medical segment (which is the group's main source of income)

    Zhitong·
    HK
    02393
    -1.74%
    Zhitong·
    HK
    02393
    -1.74%
    © 2025 Longbridge｜Disclaimer